CANCER LETT 润色咨询

CANCER LETTERS

出版年份：1975 年文章数：4498 投稿命中率： 开通期刊会员，数据随心看

出版周期：Biweekly 自引率：3.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-25 princesun083

    很有可能，如果今年最终因子6.4的话果然 2017-02-24 发表::
    这个杂志今年会被调到一区嘛？

    果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-24 果然

    这个杂志今年会被调到一区嘛？

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-24 123456jinwei

    请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-24 Dr. H

    肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-23 zzcpla

    给的大修，修回后uderreview两天了。不知道什么时候有消息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-19 zzcpla

    多长时间呀，我的也是大修pes 2017-02-15 发表::
    大修二审后昨天变成dicision了，不知多久能出结果

    pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-15 pes

    大修二审后昨天变成dicision了，不知多久能出结果

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-03 ppjianren

    小修吗vivid826 2017-02-03 发表::
    研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept

    vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-02-03 vivid826

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=533337, encodeId=43b253333ec3, content=很有可能，如果今年最终因子6.4的话<span class="quote">果然 2017-02-24 发表::<br>这个杂志今年会被调到一区嘛？</span>, beContent=果然 2017-02-24 发表:: 这个杂志今年会被调到一区嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Sat Feb 25 00:08:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533334, encodeId=f82053333464, content=这个杂志今年会被调到一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f52026272, createdName=果然, createdTime=Fri Feb 24 23:24:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533322, encodeId=c345533322dc, content=请问要求3500字是指哪些部分，还是全部文章字数限制呢，初次投稿请大家指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d70b2026087, createdName=123456jinwei, createdTime=Fri Feb 24 16:40:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533319, encodeId=f04853331952, content=肿瘤免疫方向的综述容不容易中？求各位老师交流经验啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Fri Feb 24 14:53:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533225, encodeId=7c6053322536, content=给的大修，修回后uderreview两天了。不知道什么时候有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Thu Feb 23 08:03:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533041, encodeId=0c35533041f0, content=多长时间呀，我的也是大修<span class="quote">pes 2017-02-15 发表::<br>大修二审后昨天变成dicision了，不知多久能出结果</span>, beContent=pes 2017-02-15 发表:: 大修二审后昨天变成dicision了，不知多久能出结果, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sun Feb 19 04:03:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532837, encodeId=8cdd53283efb, content=大修二审后昨天变成dicision了，不知多久能出结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa7c1714806, createdName=pes, createdTime=Wed Feb 15 02:44:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532440, encodeId=f720532440b4, content=小修吗<span class="quote">vivid826 2017-02-03 发表::<br>研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept</span>, beContent=vivid826 2017-02-03 发表:: 研究方向：肿瘤分子生物学;; 接收率：约25% 审稿时间：约1个月 总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/11/ef53abc18e58b2db046023b8811f6e87.jpg, createdBy=48dd105950, createdName=ppjianren, createdTime=Fri Feb 03 18:28:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532417, encodeId=24c153241e60, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：总体来说比较快！11.22投稿，但12.16号才受理，2017.1.10返修意见，在2017.1.26认真回复意见后当天accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34ac90650, createdName=vivid826, createdTime=Fri Feb 03 09:23:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532320, encodeId=7f515323205f, content=共同加油<span class="quote">18753107090(暂无匿称) 2017-01-28 发表::<br>效率还是蛮高的啊，我刚投了一篇，期待中！</span>, beContent=18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9a41456963, createdName=zzcpla, createdTime=Sat Jan 28 12:02:00 CST 2017, time=2017-01-28, status=1, ipAttribution=)]
    2017-01-28 zzcpla

    共同加油18753107090(暂无匿称) 2017-01-28 发表::
    效率还是蛮高的啊，我刚投了一篇，期待中！

    18753107090(暂无匿称) 2017-01-28 发表:: 效率还是蛮高的啊，我刚投了一篇，期待中！

    0

共500条页码: 48/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分